CDK4/6 inhibitors with hormonal therapy have become the standard of care for first and second-line therapy for hormone receptor-positive HER2-negative metastatic BC. Unfortunately, the long-term treatment cost of CDK4/6 inhibitors is prohibitive leading to non-compliance and loss of follow-up. To increase access and compliance for patients with breast cancer we used generic palbociclib in our patients. Here, we report the data on 33 patients using generic palbociclib. For generic Palbociclib progression-free survival was 14 months. .

Keywords: Metastatic Breast Cancer (MBC); CDK4/6; Toxicity

References

1. N Hortobagyi., et al. “Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer”. The New England Journal of Medicine 386 (2022): 942-950.
2. Dennis J Slamon., et al. “Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer”. The New England Journal of Medicine 382 (2020): 514-524.
3. Seock-Ah Im., et al. “Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer”. The New England Journal of Medicine 381 (2019): 307-316.
4. Nicole M Engel-Nitz., et al. “Palbociclib Adherence and Persistence in Patients with Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer”. Patient Prefer Adherence 17 (2023): 1049-1062.
5. World Bank Data Pakistan (2023).
6. Tannock F., et al. “Near-Equivalence: Generating Evidence to Support Alternative cost-effective Treatments”. JCO 9 (2021).
7. Gabe S Sonke., et al. “Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)”. JCO17 (2023).
8. Andreea-Iuliana Miron., et al. “Real-world outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania”. Diagnostics (Basel) 11 (2023): 1938.

Citation

Citation: Zeba Aziz and Zeeshan Ahmed Khan Niazi. “To Determine the Cost Effectiveness and Efficacy of Generic Palbociclib in Resource-Limited Countries”.Acta Scientific Cancer Biology 7.10 (2023): 42-44.

Copyright

Copyright: © 2023 Zeba Aziz and Zeeshan Ahmed Khan Niazi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.